Kelly Culwell, MD, Joins as Head of Research and Development, Women’s Health with a Focus on Innovative Products That Meet Women’s Needs ROSWELL, Ga., Nov. 15, 2022 /PRNewswire/ — Sebela Pharmaceuticals® today announced a new division of the company named Sebela Women’s Health along with the appointment of Kelly Culwell, MD, as Head of Research and Development for the… Read more »
Sebela Pharmaceuticals® Acquires Exclusive Licensing Rights to Develop and Commercialize Tegoprazan in the U.S. and Canada Phase 3 Trials Initiated with Tegoprazan for the Treatment of Erosive Esophagitis and Non-erosive Reflux Disease Sebela Pharmaceuticals® has entered an exclusive partnership with HK inno.N Corporation to license tegoprazan in the United States and Canada. Under the agreement, Braintree Laboratories, a leader… Read more »
Fort Worth, Texas, April 1, 2022. As the Nation’s leading provider of inspection, maintenance, repair and specialized construction services for industrial railroad infrastructure, American Track is proud to announce the acquisition of The Railroad Associates Corp (TRAC) in Boiling Springs, PA. In 2021 DFW Capital Partners acquired American Track and has assisted with an aggressive… Read more »
For Immediate Release March 31, 2022 Teaneck, NJ DFW Capital Partners announced today that Patrick Fairfield has been promoted to the position of Vice President. Based in the firm’s Teaneck, NJ office, Pat joined DFW in 2017 as an Associate. Pat has been actively involved in deal execution, debt financing arrangement and portfolio monitoring for… Read more »
For Immediate Release January 12, 2022 Teaneck, NJ DFW Capital Partners successfully exits its investment in Children’s Dental Management DFW Capital Partners (“DFW”) is pleased to announce that it has completed the sale of its portfolio company, CDHA Holdings, LLC (“Children’s Dental Management”, “CDM” or the “Company”). CDM is the largest pediatric specialist-led dental support… Read more »
BRIDGEWATER, N.J. & ROSWELL, Ga.–(BUSINESS WIRE)–Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) and Saol Therapeutics, a private specialty pharmaceutical company (“Saol”), today announced a definitive agreement under which Amneal will acquire Saol’s Baclofen franchise, including Lioresal® and LYVISPAHTM as well as a pipeline product under development. The acquisition expands Amneal’s commercial institutional and specialty portfolio in neurology while… Read more »